The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Name

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Legal name

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Website

https://nichd.nih.gov

Company type

Public

Founded year

1962

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

NICHD is a U.S. federal research institute within NIH that funds and conducts biomedical research on child, maternal, and reproductive health, disseminating public health information and operating programs including the Pediatric Trials Network and Safe to Sleep.

Ownership category

akta.pro rank

Product category

Federal Biomedical Research

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Newborn Screening & Genetic Public Health Laboratories (HLAJAIAJ)

akta.pro secondary industries

Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Preterm/NICU-Transition Newborn Care (NCS) (HSAAACAF)

Keywords

• Pediatric clinical research
• Maternal health research
• Reproductive health research
• Biomedical research funding
• Medical rehabilitation research

Headquarters

HQ city

Rockville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Others

Revenue model

1. Federal Government Appropriations: NICHD receives annual congressional appropriations as part of the National Institutes of Health (NIH) budget to conduct and support research, training, health information dissemination, and other programs.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

NICHD conducts intramural biomedical research across more than 40 specialized labs and funds extramural research through grants and contracts on child health, maternal health, reproductive health, intellectual and developmental disabilities, and medical rehabilitation. It operates the BPCA program and Pediatric Trials Network to drive pediatric drug label changes through FDA, runs public health education campaigns such as Safe to Sleep and the National Child and Maternal Health Education Program, and disseminates free health information through its A-Z topics portal, publications, and ClinicalTrials.gov.

Product overview

NICHD is a federal research institute within the NIH that does not offer commercial products. Instead, it provides health information resources, research programs, and publications focused on child health, human development, and maternal health. Key offerings include the Best Pharmaceuticals for Children Act (BPCA) program supporting pediatric drug labeling research, the Pediatric Trials Network (PTN) for clinical drug trials, health topics A-Z information pages, publications and materials, clinical trial listings via ClinicalTrials.gov, and educational campaigns such as Safe to Sleep. The institute's research spans gynecology, pregnancy, childhood development, intellectual disabilities, and medical rehabilitation.

Differentiator

Problem solved

Functional benefit

Brands

• Safe to Sleep: A campaign to reduce sudden infant death syndrome (SIDS) and other sleep-related infant deaths.
• National Child and Maternal Health Education Program
• Best Pharmaceuticals for Children Act (BPCA) Program
• Pediatric Trials Network (PTN)

Products and services

• Safe to Sleep Campaign A public education campaign focused on infant sleep safety and SIDS prevention, providing resources for caregivers and healthcare providers to reduce sudden infant death syndrome and other sleep-related infant deaths.
• National Child and Maternal Health Education Program (NCMHEP) An education initiative addressing maternal and child health topics through coordinated programs and resources for healthcare providers and the public.
• Best Pharmaceuticals for Children Act (BPCA) Program A mandated program that identifies drugs needing pediatric study, sponsors clinical trials through the Pediatric Trials Network, and submits data to FDA for label change considerations to improve pediatric medication safety and dosing.
• Pediatric Trials Network (PTN) A research network operated by Duke Clinical Research Institute to conduct safe and effective pediatric clinical drug trials for a variety of therapeutic areas and medical devices, enabling pediatric label changes.
• NICHD Health Topics A-Z Comprehensive health information covering conditions from adrenal gland disorders to vulvodynia, including pregnancy, endometriosis, autism, and intellectual disabilities, provided as a public information resource.
• NICHD Publications Downloadable and orderable publications and materials providing health information for caregivers, healthcare providers, and the general public.

Quantifiable outcome

• Infant mortality rates decreased by over 70% in the United States
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and major.

• Duke Clinical Research Institute (DCRI)coreStrategic or Co-development Partner · 1 September 2010In September 2010, NICHD awarded a contract to Duke Clinical Research Institute to launch the Pediatric Trials Network (PTN). DCRI manages PTN to conduct safe and effective pediatric clinical trials for a variety of therapeutic areas and medical devices under BPCA.
• U.S. Food and Drug Administration (FDA)coreStrategic or Co-development PartnerNICHD collaborates with FDA to submit pediatric clinical study data for label change consideration. BPCA program submits trial results to FDA for evaluation and additional analyses in consideration of drug label modifications for pediatric populations.
• Other NIH InstitutesmajorStrategic or Co-development PartnerNICHD collaborates with other NIH institutes to maximize research outcomes, share resources, and coordinate on cross-cutting health issues including drug development and pediatric research initiatives.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• National Cancer Institute (NCI): Another NIH institute that conducts intramural research, funds extramural grants, runs large clinical trial networks, and translates research into public health impact — structurally identical operating model to NICHD.
• National Institute of Mental Health (NIMH): Sister NIH institute with the same funding model, intramural/extramural research split, and public health dissemination function; comparable in scale, governance, and operational cadence.
• National Heart, Lung, and Blood Institute (NHLBI): NIH institute that similarly funds investigator-initiated research, operates major clinical trials, and disseminates evidence-based guidelines — a close structural analog to NICHD.
• March of Dimes: Non-profit foundation focused on maternal and infant health, funding research, running public education campaigns (e.g., on prematurity), and advocating for newborn screening — directly comparable mission and end beneficiaries.
• Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Centers (IDDRC Network): NICHD-funded network of academic centers conducting research on intellectual and developmental disabilities, operating with a similar extramural-grant and clinical-research model.

Broad incumbents

• Centers for Disease Control and Prevention (CDC): Federal public health agency that operates public health campaigns, surveillance, and guidelines at national scale; broader mission but overlapping public-health dissemination and newborn screening roles.
• U.S. Food and Drug Administration (FDA): Federal regulator that is the regulatory counterparty to NICHD's BPCA program; its pediatric and rare-disease review functions overlap with NICHD's translational outputs.

Others

• Bill & Melinda Gates Foundation (Global Health): Large philanthropic funder of maternal, newborn, and child health research globally; comparable funding scale and target outcomes though structurally different from a federal agency.
• World Health Organization (WHO): International body setting guidelines and funding research on maternal, newborn, and child health, with overlapping public-health dissemination and standards-setting roles.

Regional players

• Children's Hospital of Philadelphia (CHOP) Research Institute: Major pediatric academic research center that conducts intramural pediatric research, runs clinical trials, and is a frequent NICHD extramural grantee and PTN collaborator.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/nichdvideos?feature=results_main
• Facebookfacebook.com/nichdgov
• LinkedInlinkedin.com/company/eunice-kennedy-shriver-national-institute-of-child-health-and-human-development-nichd
• Instagraminstagram.com/nichd_nih
• Xx.com/nichd_nih

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments34 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)